J & H Besta Corp. of Hicksville, New York, has been informed by the Food and Drug Administration (FDA) that FDA lab analysis of Slim-30 Herb Supplement distributed by the company was found to contain undeclared N-Desmethyl Sibutramine and traces of Sibutramine. Sibutramine is an FDA-approved drug used as an appetite suppressant for weight loss. […]
J & H Besta Corp. of Hicksville, New York, has been informed by the Food and Drug Administration (FDA) that FDA lab analysis of <"https://www.yourlawyer.com/practice_areas/defective_drugs">Slim-30 Herb Supplement distributed by the company was found to contain undeclared N-Desmethyl Sibutramine and traces of Sibutramine. Sibutramine is an FDA-approved drug used as an appetite suppressant for weight loss. The FDA has not approved this product, therefore the safety and efficacy of the product is unknown.
FDA advises that this product poses a threat to consumers because Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Slim-30 Herb Supplement is marketed as a Natural Herb for Weight Loss. Slim-30 Herb Supplement is packaged in plastic bottles containing 30 capsules per bottle and bears UPC 8 31457 005009 2. The affected lot/code being recalled is 032009.
The product was sold to distributors and retail stores nationwide and China and via Internet sales. To date, no illnesses or injuries have been reported to the company in connection with this product.
J & H Besta Corporation has discontinued distribution of this affected product lot.
The FDA is advising consumers to not take the Slim-30 Herb Supplement and to return it immediately to the place of purchase for a full refund. Consumers with questions should contact Jason Wang at 516-735-1436, Monday through Friday, 10:00 am to 5:30 pm, Eastern Daylight Time.
Any adverse reactions experienced with the use of the recalled Slim-30 Herb Supplement may be reported to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program online at www.fda.gov/MedWatch/report.htm; by phone at 1-800-332-1088 ; or by returning the postage-paid FDA form 3500 ; by mail ; or by fax at 1-800-FDA-0178.
